# Pasithea Therapeutics Corp.: overview

KTTA · Nasdaq · CIK 1841330 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ktta.md) · [Financials](/companies/ktta/financials.md) · [Filings](/companies/ktta/filings.md) · [Insiders](/companies/ktta/insiders.md)

Latest reported revenue: [$240.7k](/filings/0001213900-23-024755.md) for Q4 FY2022, three months to 2022-12-31, from the 10-K filed Mar 30, 2023 (XBRL us-gaap:Revenues, accession 0001213900-23-024755).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(2.87)](/filings/0001213900-25-110093.md) | not reported | [(1.61)](/filings/0001213900-26-057837.md) | [(0.66)](/filings/0001213900-26-090146.md) | [(0.41)](/filings/0001213900-25-110093.md) | not reported | [(0.12)](/filings/0001213900-26-057837.md) | [(0.16)](/filings/0001213900-26-090146.md) |
| Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001213900-23-024755.md) | [0.5](/filings/0001213900-23-024755.md) | not reported | not reported | not reported |
| Gross margin | % | [(14.7%)](/filings/0001213900-22-016160.md) | not reported | not reported | not reported | not reported |
| Operating margin | % | [(29925.7%)](/filings/0001213900-23-024755.md) | [(2587.3%)](/filings/0001213900-24-027508.md) | not reported | not reported | not reported |
| Net margin | % | [(14430.5%)](/filings/0001213900-23-024755.md) | [(2864.3%)](/filings/0001213900-24-027508.md) | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.21)](/filings/0001213900-23-024755.md) | [(1.76)](/filings/0001213900-24-027508.md) | [(0.42)](/filings/0001013762-25-001646.md) | [(12.69)](/filings/0001213900-26-036434.md) | [(2.91)](/filings/0001213900-26-036434.md) |
| Free cash flow | $m | [(3.2)](/filings/0001213900-23-024755.md) | [(14.7)](/filings/0001213900-23-024755.md) | [(12.8)](/filings/0001013762-25-001646.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ktta/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $1.6m | 2,100,000 |  | Not compared |
| [Cable Car Capital, LP](/funds/1699575.md) | 2026-06-30 | $1.5m | 3,000,000 |  | Added +1,793,621 |
| [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $1.1m | 2,201,468 |  | Added +1,370,167 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $1.1m | 2,100,000 |  | Not compared |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $1.1m | 2,100,000 |  | Unchanged |
| [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $1.1m | 2,050,000 |  | New +2,050,000 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $961.0k | 1,864,485 |  | Added +513,589 |
| [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $515.4k | 1,000,000 |  | Reduced −1,100,000 |
| [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $483.2k | 937,550 |  | Added +600,042 |
| [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $239.9k | 465,471 |  | Reduced −1,634,529 |

## Recent filings

[All 341 filings](/companies/ktta/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-16 | 16:06 ET | [8-K](/filings/0001213900-26-100515.md) | 8.01 Other events | 0001213900-26-100515 |
| 2026-09-09 | 16:20 ET | [8-K](/filings/0001213900-26-098405.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-098405 |
| 2026-08-21 | 17:05 ET | [8-K](/filings/0001213900-26-092672.md) | 3.01 Delisting notice | 0001213900-26-092672 |
| 2026-08-14 | 16:30 ET | [10-Q](/filings/0001213900-26-090146.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090146 |
| 2026-08-07 | 17:15 ET | [DEF 14A](/filings/0001213900-26-086799.md) | Proxy statement, period 2026-09-09 | 0001213900-26-086799 |
| 2026-05-15 | 16:30 ET | [10-Q](/filings/0001213900-26-057837.md) | Quarterly report, period 2026-03-31 | 0001213900-26-057837 |
| 2026-05-04 | 17:00 ET | [8-K](/filings/0001213900-26-051681.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-051681 |
| 2026-03-30 | 17:33 ET | [10-K](/filings/0001213900-26-036434.md) | Annual report, period 2025-12-31 | 0001213900-26-036434 |
| 2026-02-20 | 17:00 ET | [8-K](/filings/0001213900-26-018874.md) | 3.01 Delisting notice | 0001213900-26-018874 |
| 2026-01-28 | 16:15 ET | [8-K](/filings/0001213900-26-008828.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-008828 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-036434.md), filed Mar 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1841330
- Tickers: KTTA
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.